NCT05373680CompletedPhase 2/3
Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression
Clinical Study Evaluating the Efficacy and Safety of Metformin Versus Empagliflozin for Halting Chronic Kidney Disease Progression
Source: ClinicalTrials.gov · Last updated 14 Aug 2025
Brief summary (registry, in English)
This randomized controlled trial aims at evaluating the efficacy and safety of the antidiabetics metformin versus empagliflozin on chronic kidney disease (CKD) progression in patients with CKD stages 2 or/and 3.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 118 (actual)
- First submitted
- 18 Feb 2022
- Start date
- 1 Jan 2022
- Primary completion date
- 1 Apr 2024
- Lead sponsor
- Tanta University
- Diseases
- Chronic kidney disease
- NCT number
- NCT05373680
What you commit to
- Study type: Interventional · Phase 2/3
- Participants enrolled: 118
- From 1 Jan 2022 to the primary completion date, 1 Apr 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Planned coronary or surgical interventions.
Other illness
- Type 1 diabetes.
- Patients with known hepatic cell failure.
- Decompensated heart requiring acute management.
- Active malignancy.
- Known hypersensitivity to study medications.
- Chronic inflammation, trauma, or infection.
Lab values
- Patients with eGFR ˂30 ml/min/1.73 m2.
- Patients already on metformin or a sodium-glucose cotransporter-2 (SGLT2) inhibitor.
Other
- Pregnant or lactating women.
- Any of the study treatments labeled contraindications.
Who the study is looking for
- Patients with mild or/and moderate chronic kidney disease (stages 2 or/and 3, estimated glomerular filtration rate (eGFR) between 30-89 ml/min/1.73 m2) at the time of the baseline visit.
- Patients with and without type 2 diabetes.
- Patients with or without proteinuria.
- Age: ≥ 18 years.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mansoura University Coordinator of this site? Confirm its status | Al Mansurah | Egypt | Unknown status |
| Tanta University Teaching Hospitals Coordinator of this site? Confirm its status | Tanta | Egypt | Unknown status |
Related publications
- Efficacy and safety of metformin versus empagliflozin on chronic kidney disease progression (MET-EMPA-CKD): a randomized controlled trial.Diabetol Metab Syndr · 2025 · PMID 41373013
- Metformin for preventing the progression of chronic kidney disease.Cochrane Database Syst Rev · 2024 · PMID 38837240
This page is information, not medical advice. Discuss any trial with your doctor.